248 related articles for article (PubMed ID: 28067073)
21. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
22. Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research.
Aprile G; Giuliani F; Cordio S; Sartore-Bianchi A; Bencardino K; Ongaro E; Martines C; Giampieri R; Bordonaro R; Siena S; Cascinu S; Scartozzi M
Future Oncol; 2014 May; 10(7):1125-8. PubMed ID: 24947252
[TBL] [Abstract][Full Text] [Related]
23. Molecular markers in gastrointestinal cancer: targeted therapy and tailored chemotherapy.
Lenz HJ
Onkologie; 2004 Feb; 27(1):12-4. PubMed ID: 15017995
[No Abstract] [Full Text] [Related]
24. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
[TBL] [Abstract][Full Text] [Related]
26. [Gastrointestinal stromal tumors (GIST)].
Reichardt P; Reichardt A
Dtsch Med Wochenschr; 2013 Oct; 138(40):2013-6. PubMed ID: 24065407
[No Abstract] [Full Text] [Related]
27. Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors.
Yan W; Zhang A; Powell MJ
Chin J Cancer; 2016 Jul; 35(1):68. PubMed ID: 27443349
[TBL] [Abstract][Full Text] [Related]
28. Clinical and cost outcomes following genomics-informed treatment for advanced cancers.
Weymann D; Pollard S; Chan B; Titmuss E; Bohm A; Laskin J; Jones SJM; Pleasance E; Nelson J; Fok A; Lim H; Karsan A; Renouf DJ; Schrader KA; Sun S; Yip S; Schaeffer DF; Marra MA; Regier DA
Cancer Med; 2021 Aug; 10(15):5131-5140. PubMed ID: 34152087
[TBL] [Abstract][Full Text] [Related]
29. Next generation sequencing technologies in cancer diagnostics and therapeutics: A mini review.
Li W; Zhao K; Kirberger M; Liao W; Yan Y
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(5):91-102. PubMed ID: 26522064
[TBL] [Abstract][Full Text] [Related]
30. Genomic pathobiology of gastric carcinoma.
Katoh H; Ishikawa S
Pathol Int; 2017 Feb; 67(2):63-71. PubMed ID: 28004449
[TBL] [Abstract][Full Text] [Related]
31. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma.
Tänzer M; Liebl M; Quante M
Pharmacol Ther; 2013 Nov; 140(2):133-47. PubMed ID: 23791941
[TBL] [Abstract][Full Text] [Related]
32. Targeted ultra-deep sequencing unveils a lack of driver-gene mutations linking non-hereditary gastrointestinal stromal tumors and highly prevalent second primary malignancies: random or nonrandom, that is the question.
Lai BR; Wu YT; Kuo YC; Hsu HC; Chen JS; Chen TC; Wu RC; Chiu CT; Yeh CN; Yeh TS
Oncotarget; 2016 Dec; 7(50):83270-83277. PubMed ID: 27806309
[TBL] [Abstract][Full Text] [Related]
33. Translating genomic research into clinical practice: promise and pitfalls.
Sparano JA; Ostrer H; Kenny PA
Am Soc Clin Oncol Educ Book; 2013; ():15-23. PubMed ID: 23714445
[TBL] [Abstract][Full Text] [Related]
34. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
35. Biomarkers for personalized medicine in GI cancers.
Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
[TBL] [Abstract][Full Text] [Related]
36. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
37. Future diagnostic and therapeutic trends in endocrine cancers.
Spiegel AM; Libutti SK
Semin Oncol; 2010 Dec; 37(6):691-5. PubMed ID: 21167386
[TBL] [Abstract][Full Text] [Related]
38. Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream.
Mack SC; Northcott PA
J Clin Oncol; 2017 Jul; 35(21):2346-2354. PubMed ID: 28640705
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
40. Designing transformative clinical trials in the cancer genome era.
Sleijfer S; Bogaerts J; Siu LL
J Clin Oncol; 2013 May; 31(15):1834-41. PubMed ID: 23589555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
